Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.94.

A number of analysts have weighed in on the stock. Evercore ISI restated an “in-line” rating and issued a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Robert W. Baird cut Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. D. Boral Capital reissued a “buy” rating and set a $12.00 price target on shares of Carisma Therapeutics in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th.

Institutional Trading of Carisma Therapeutics

Several institutional investors have recently added to or reduced their stakes in CARM. Wexford Capital LP lifted its position in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the period. Renaissance Technologies LLC raised its stake in Carisma Therapeutics by 11.9% during the fourth quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after buying an additional 24,600 shares during the last quarter. Finally, Barclays PLC boosted its position in Carisma Therapeutics by 3,661,933.3% during the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after acquiring an additional 549,290 shares during the last quarter. 44.27% of the stock is currently owned by institutional investors.

Carisma Therapeutics Stock Down 7.8 %

CARM stock opened at $0.33 on Friday. The firm has a 50-day moving average price of $0.44 and a 200-day moving average price of $0.67. Carisma Therapeutics has a 12 month low of $0.33 and a 12 month high of $2.30. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The stock has a market capitalization of $13.78 million, a P/E ratio of -0.21 and a beta of 1.55.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.